|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer research.
|
28718425 |
2017 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
In this study, human clinical data from The Cancer Genome Atlas database revealed that increased NLRC5 expression was associated with advanced stage and poor prognosis in ccRCC patients.
|
30543814 |
2019 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
|
27162338 |
2016 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.
|
30706093 |
2019 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Better awareness of the multiple roles of NLRC5 will help to define its overall contribution to immune responses and cancer.
|
28261210 |
2017 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Given the importance of CD8<sup>+</sup> T and NK cells in controlling infection and cancer, it is not surprising that NLRC5 is also starting to emerge as a central player in these diseases.
|
28215281 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5 is an interferon γ-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival.
|
29762254 |
2018 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer research.
|
28718425 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Better awareness of the multiple roles of NLRC5 will help to define its overall contribution to immune responses and cancer.
|
28261210 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Given the importance of CD8<sup>+</sup> T and NK cells in controlling infection and cancer, it is not surprising that NLRC5 is also starting to emerge as a central player in these diseases.
|
28215281 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
|
27162338 |
2016 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5 is an interferon γ-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival.
|
29762254 |
2018 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.
|
30706093 |
2019 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
In this study, human clinical data from The Cancer Genome Atlas database revealed that increased NLRC5 expression was associated with advanced stage and poor prognosis in ccRCC patients.
|
30543814 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Mutations affecting the HLA class I transactivator NLRC5 were observed as a potential new immune evasion mechanism in 26% (6% abrogating) of the analyzed tumors.
|
29900056 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Thus, our findings suggest that NLRC5 may play an important role in progression of HCC and provide a potential therapeutic value in this tumor.
|
26975630 |
2016 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
NLRC5 expression was significantly related to lymph nodes and tumor node metastasis (TNM) staging (χ<sup>2</sup>=6.295; χ<sup>2</sup>=6.268).
|
30426081 |
2018 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
CITA/NLRC5 plays a crucial role in human cancer immunity through the recruitment and activation of tumor killing CD8+ T cells.
|
30706093 |
2019 |
|
Fibrosis, Liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
NLRC5, as the largest member of nucleotide-binding domain and leucine-rich repeat (NLRs) family, has recently been implicated in the development of hepatic fibrosis.
|
27525969 |
2016 |
|
Fibrosis, Liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
NLRC5 inhibition would be a promising therapeutic avenue for treating hepatic fibrosis.
|
26592197 |
2016 |
|
Fibrosis, Liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
As the largest member of the nucleotide‑binding domain and leucine‑rich repeat (NLR) family, NLRC5 has been shown to be pivotal in the development of hepatic fibrosis.
|
28713900 |
2017 |
|
Fibrosis, Liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
To investigate the role of NLRC5 in the activation and reversion of HSCs induced with transforming growth factor-β (TGF-β) and MDI, and to explore its relationship with liver fibrosis.
|
31293340 |
2019 |
|
Virus Diseases
|
0.030 |
AlteredExpression
|
group |
BEFREE |
When the modulation of NLRC5 in pathogen infection was analyzed, it was found that zebrafish NLRC5 was upregulated by both bacterial and viral infection.
|
27876605 |
2017 |
|
Virus Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Therefore, our study highlights how NLRC5 regulates multiple immune effector mechanisms to promote the host defense during influenza virus infection.
|
28615208 |
2017 |
|
Virus Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Here, we take advantage of the rotavirus model in adult mice to dissect the impact of NLRC5 on CD8<sup>+</sup> T-cell responses to this viral infection at the gut mucosa.
|
30768806 |
2019 |